<li>acarbose<p>dexamethasone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>albendazole<p>dexamethasone increases levels of albendazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>alfentanil<p>dexamethasone will decrease the level or effect of alfentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>alfuzosin<p>dexamethasone will decrease the level or effect of alfuzosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>alosetron<p>dexamethasone will decrease the level or effect of alosetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>ambrisentan<p>dexamethasone will decrease the level or effect of ambrisentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>amitriptyline<p>dexamethasone will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>amlodipine<p>dexamethasone will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>amphotericin b deoxycholate<p>amphotericin b deoxycholate, dexamethasone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential for hypokalemia.</p></li><li>armodafinil<p>dexamethasone will decrease the level or effect of armodafinil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>aspirin<p>dexamethasone decreases levels of aspirin by increasing renal clearance. Minor/Significance Unknown.</p></li><li>aspirin rectal<p>dexamethasone decreases levels of aspirin rectal by increasing renal clearance. Minor/Significance Unknown.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>dexamethasone decreases levels of aspirin/citric acid/sodium bicarbonate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>atazanavir<p>dexamethasone will decrease the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>balsalazide<p>dexamethasone decreases levels of balsalazide by increasing renal clearance. Minor/Significance Unknown.</p></li><li>bendroflumethiazide<p>dexamethasone, bendroflumethiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>bosentan<p>dexamethasone will decrease the level or effect of bosentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>bumetanide<p>dexamethasone, bumetanide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>calcium acetate<p>dexamethasone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown.</p></li><li>calcium carbonate<p>dexamethasone decreases levels of calcium carbonate by increasing elimination. Minor/Significance Unknown.</p></li><li>calcium chloride<p>dexamethasone decreases levels of calcium chloride by increasing elimination. Minor/Significance Unknown.</p></li><li>calcium citrate<p>dexamethasone decreases levels of calcium citrate by increasing elimination. Minor/Significance Unknown.</p></li><li>calcium gluconate<p>dexamethasone decreases levels of calcium gluconate by increasing elimination. Minor/Significance Unknown.</p></li><li>caspofungin<p>dexamethasone decreases levels of caspofungin by increasing metabolism. Minor/Significance Unknown.</p></li><li>cevimeline<p>dexamethasone will decrease the level or effect of cevimeline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>chlorothiazide<p>dexamethasone, chlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>chlorpropamide<p>dexamethasone decreases effects of chlorpropamide by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>chlorthalidone<p>dexamethasone, chlorthalidone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>choline magnesium trisalicylate<p>dexamethasone decreases levels of choline magnesium trisalicylate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>chromium<p>dexamethasone decreases levels of chromium by increasing renal clearance. Minor/Significance Unknown.</p></li><li>clarithromycin<p>dexamethasone will decrease the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>clomethiazole<p>dexamethasone will decrease the level or effect of clomethiazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>clomipramine<p>dexamethasone will decrease the level or effect of clomipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>colestipol<p>colestipol decreases levels of dexamethasone by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>cyclopenthiazide<p>dexamethasone, cyclopenthiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>cyclosporine<p>dexamethasone, cyclosporine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown.</p></li><li>danazol<p>danazol, dexamethasone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>dapsone<p>dexamethasone will decrease the level or effect of dapsone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>delavirdine<p>dexamethasone will decrease the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>desipramine<p>dexamethasone will decrease the level or effect of desipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>diflunisal<p>dexamethasone decreases levels of diflunisal by increasing renal clearance. Minor/Significance Unknown.</p></li><li>disopyramide<p>dexamethasone will decrease the level or effect of disopyramide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>docetaxel<p>dexamethasone will decrease the level or effect of docetaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>donepezil<p>dexamethasone will decrease the level or effect of donepezil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>dutasteride<p>dexamethasone will decrease the level or effect of dutasteride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>efavirenz<p>dexamethasone will decrease the level or effect of efavirenz by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>eplerenone<p>dexamethasone will decrease the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>esomeprazole<p>dexamethasone will decrease the level or effect of esomeprazole by  increasing metabolism. Minor/Significance Unknown.</p></li><li>ethacrynic acid<p>dexamethasone, ethacrynic acid. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>etoricoxib<p>dexamethasone will decrease the level or effect of etoricoxib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>eucalyptus<p>dexamethasone will decrease the level or effect of eucalyptus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>feverfew<p>dexamethasone decreases effects of feverfew by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>finasteride<p>dexamethasone will decrease the level or effect of finasteride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>fluoxymesterone<p>fluoxymesterone, dexamethasone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>fluvoxamine<p>fluvoxamine will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>furosemide<p>dexamethasone, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>galantamine<p>dexamethasone will decrease the level or effect of galantamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>glimepiride<p>dexamethasone decreases effects of glimepiride by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>glipizide<p>dexamethasone decreases effects of glipizide by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>gliquidone<p>dexamethasone decreases effects of gliquidone by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>glyburide<p>dexamethasone decreases effects of glyburide by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>hydrochlorothiazide<p>dexamethasone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>imatinib<p>dexamethasone will decrease the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>imipramine<p>dexamethasone will decrease the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>indapamide<p>dexamethasone, indapamide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>insulin aspart<p>dexamethasone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>insulin detemir<p>dexamethasone decreases effects of insulin detemir by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>insulin glargine<p>dexamethasone decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>insulin glulisine<p>dexamethasone decreases effects of insulin glulisine by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>insulin lispro<p>dexamethasone decreases effects of insulin lispro by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>insulin nph<p>dexamethasone decreases effects of insulin nph by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>insulin regular human<p>dexamethasone decreases effects of insulin regular human by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>isoniazid<p>dexamethasone decreases effects of isoniazid by unknown mechanism. Minor/Significance Unknown.</p></li><li>isradipine<p>dexamethasone will decrease the level or effect of isradipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>itraconazole<p>dexamethasone will decrease the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>ketoconazole<p>dexamethasone will decrease the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>lansoprazole<p>dexamethasone will decrease the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>mesalamine<p>dexamethasone decreases levels of mesalamine by increasing renal clearance. Minor/Significance Unknown.</p></li><li>mesterolone<p>mesterolone, dexamethasone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>metformin<p>dexamethasone decreases effects of metformin by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>methyclothiazide<p>dexamethasone, methyclothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>methyltestosterone<p>methyltestosterone, dexamethasone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>metolazone<p>dexamethasone, metolazone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>metyrapone<p>dexamethasone decreases effects of metyrapone by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>mibefradil<p>dexamethasone will decrease the level or effect of mibefradil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>miglitol<p>dexamethasone decreases effects of miglitol by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>montelukast<p>dexamethasone will decrease the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>nateglinide<p>dexamethasone decreases effects of nateglinide by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>nimodipine<p>dexamethasone will decrease the level or effect of nimodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>nitrendipine<p>dexamethasone will decrease the level or effect of nitrendipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>omeprazole<p>dexamethasone will decrease the level or effect of omeprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>oxandrolone<p>oxandrolone, dexamethasone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>oxybutynin<p>dexamethasone will decrease the level or effect of oxybutynin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>oxymetholone<p>oxymetholone, dexamethasone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>paclitaxel<p>dexamethasone will decrease the level or effect of paclitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>paclitaxel protein bound<p>dexamethasone will decrease the level or effect of paclitaxel protein bound by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>pantoprazole<p>dexamethasone will decrease the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>parecoxib<p>dexamethasone will decrease the level or effect of parecoxib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>pimozide<p>dexamethasone will decrease the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>pioglitazone<p>dexamethasone will decrease the level or effect of pioglitazone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.<span><br><br></span>dexamethasone decreases effects of pioglitazone by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>porfimer<p>dexamethasone decreases levels of porfimer by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>propafenone<p>dexamethasone will decrease the level or effect of propafenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>quinine<p>dexamethasone will decrease the level or effect of quinine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>rabeprazole<p>dexamethasone will decrease the level or effect of rabeprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>ramelteon<p>dexamethasone will decrease the level or effect of ramelteon by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>repaglinide<p>dexamethasone decreases effects of repaglinide by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>rosiglitazone<p>dexamethasone decreases effects of rosiglitazone by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>salicylates (non-asa)<p>dexamethasone decreases levels of salicylates (non-asa) by increasing renal clearance. Minor/Significance Unknown.</p></li><li>salsalate<p>dexamethasone decreases levels of salsalate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>sargramostim<p>dexamethasone increases effects of sargramostim by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>saxagliptin<p>dexamethasone will decrease the level or effect of saxagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.<span><br><br></span>dexamethasone decreases effects of saxagliptin by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>sitagliptin<p>dexamethasone decreases effects of sitagliptin by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>somatropin<p>dexamethasone decreases effects of somatropin by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>sufentanil<p>dexamethasone will decrease the level or effect of sufentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>sulfasalazine<p>dexamethasone decreases levels of sulfasalazine by increasing renal clearance. Minor/Significance Unknown.</p></li><li>tacrolimus<p>dexamethasone, tacrolimus.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown.</p></li><li>telithromycin<p>dexamethasone will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>testosterone<p>testosterone, dexamethasone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>testosterone buccal system<p>testosterone buccal system, dexamethasone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>testosterone topical<p>testosterone topical, dexamethasone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>tolazamide<p>dexamethasone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>tolbutamide<p>dexamethasone decreases effects of tolbutamide by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>torsemide<p>dexamethasone, torsemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>troglitazone<p>dexamethasone decreases effects of troglitazone by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>troleandomycin<p>dexamethasone will decrease the level or effect of troleandomycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>vesnarinone<p>dexamethasone will decrease the level or effect of vesnarinone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>vildagliptin<p>dexamethasone decreases effects of vildagliptin by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>vinblastine<p>dexamethasone will decrease the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>vincristine<p>dexamethasone will decrease the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>vincristine liposomal<p>dexamethasone will decrease the level or effect of vincristine liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>vinorelbine<p>dexamethasone will decrease the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>willow bark<p>dexamethasone decreases levels of willow bark by increasing renal clearance. Minor/Significance Unknown.</p></li><li>zaleplon<p>dexamethasone will decrease the level or effect of zaleplon by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>ziprasidone<p>dexamethasone will decrease the level or effect of ziprasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>zolpidem<p>dexamethasone will decrease the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>zonisamide<p>dexamethasone will decrease the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li>